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Objective: To assess the efficacy and safety of ultra-low dose 0.005% estriol vaginal gel in women with breast
cancer receiving nonsteroidal aromatase inhibitors (NSAIs) and experiencing treatment-related vulvovaginal
symptoms and signs.
Methods: Women with hormone receptor-positive early breast cancer receiving NSAIs were randomized to
either estriol vaginal gel or placebo for 12 weeks. Vaginal maturation, vaginal pH, and total and individual scores of
symptoms and signs of vulvovaginal atrophy were assessed at baseline and at weeks 3 and 12; sexual functioning
was also evaluated using the Female Sexual Functioning Index (FSFI) questionnaire, as well as circulating
estrogens, follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
Results: Sixty-one women with a mean age of 59 years were included: 50 received 0.005% estriol vaginal gel and 11
received placebo. Active treatment significantly improved maturation value and pH, vaginal dryness and global scores of
symptoms and signs. Active treatment also increased the total FSFI score and all the FSFI domains, with the exception of
pain. Small oscillations were observed in FSH and LH, which remained within the postmenopausal range. Estriol levels
increased initially and normalized by week 12, and estradiol and estrone remained mostly undetectable throughout the study.
Conclusions: Ultra-low dose 0.005% estriol vaginal gel showed efficacy in improving the symptoms and signs
of vulvovaginal atrophy. These results, together with minimal oscillations in hormonal levels throughout the
treatment, support the use of ultra-low dose 0.005% estriol vaginal gel as a treatment option for vulvovaginal
atrophy in women with breast cancer receiving NSAIs with an indication for treatment with vaginal estrogens.
Key Words: Aromatase inhibitors – Breast cancer – Estriol – Vaginal atrophy.Video Summary: http://links.lww.com/MENO/A531.22, 2019; revised and accepted November 4, 2019.
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R VVA IN BREAST CANCERreast cancer survivors (BCSs) who initiate adjuvant
therapy with nonsteroidal aromatase inhibitorsB (NSAIs) experience various genitourinary signs
and symptoms associated with menopausal stage. This clini-
cal condition, currently encompassed within the term ‘‘geni-
tourinary syndrome of menopause (GSM),’’ are mainly
attributed to vulvovaginal atrophy and include genital (ie
dryness, burning, and irritation), sexual (ie, lack of lubrica-
tion, discomfort, and pain), and urinary problems (ie, urgency,
dysuria, and recurrent urinary tract infections).1,2 Intense
estrogen deprivation associated with NSAI therapy increases
the severity of GSM symptoms, which negatively impact
patients’ quality of life and may consequently compromise
their compliance with adjuvant endocrine therapy.2-4
Symptoms associated with vulvovaginal atrophy appear in
50% to 75% of BCSs, the most common being vaginal dryness
and dyspareunia.5-7 To alleviate these and other vulvovaginal
symptoms such as itching and burning, vaginal moisturizers
and lubricants are recommended as first-line therapy.2,4
However, these products only provide temporary symptom-
atic relief, and do not restore the normal function of vaginal
tissue.2,4,8 Conversely, local hormonal treatments have
proven efficacy in reversing vulvovaginal atrophy associated
with estrogen depletion, although their use in BCSs is con-
troversial due to the risk of increasing estrogen levels.4,8,9
In this regard, low-dose local estrogen treatments are con-
sidered to have a lower risk profile compared to standard doses
and have shown efficacy in several studies in BCSs.10,11
Among the variety of local treatments, ultra-low dose of
0.005% estriol vaginal gel has shown a favorable pharmacoki-
netic and safety profile (ie, a negligible increase of serum estriol
levels after three weeks of daily use) and efficacy in reversing
vulvovaginal symptoms in healthy postmenopausal women
after 12 weeks of treatment.12,13 Estriol is a final metabolite
unable to convert back to other estrogenic precursors, and has
low binding affinity to the estrogen receptor. Furthermore,
estriol displays preferential affinity to b (urogenital) rather than
a (breast) estrogen receptors. Compared with estradiol, estriol
is a less potent hormone with lower estrogenic potential14; yet,
clinical studies indicate a similar effectiveness of both agents in
controlling GSM symptoms.4,8,15,16
Even though low-dose estrogen-based vaginal preparations
are widely used, scientific evidence regarding their safety and
efficacy in women with breast cancer receiving NSAI treat-
ment is still scarce, and the need for placebo-controlled
randomized trials in this setting has been highlighted.14,17,18
Given that NSAIs are a mainstay of endocrine adjuvant
treatment for breast cancer survivors, further clinical research
is needed to establish guidelines to treat its associated side
effects.4,8,9,11 In this randomized, placebo-controlled clinical
trial, we investigated the efficacy and safety of an ultra-low
dose of 0.005% estriol vaginal gel in postmenopausal women
treated with NSAIs under the hypothesis that its application is
effective in the management of vulvovaginal symptoms with-
out a significant impact on serum gonadotropins and plasma
estrogens.
LOW DOSE ESTRIOL FOMATERIAL AND METHODS
Study design and population
This was a phase II, randomized, double-blind, placebo-
controlled, international, multicenter study for assessing the
safety and efficacy of 0.005% estriol vaginal gel in the
treatment of symptoms of vulvovaginal atrophy. The study
included postmenopausal women with hormone receptor-
positive (and any HER2 status) early breast cancer (stage
I-IIIA) who had been treated with NSAI (ie, either anastrozole
or letrozole) for at least six months. Participants were
recruited from five Spanish sites and one Swedish site during
a routine follow-up visit between April 2015 and October
2016. Postmenopausal status was defined as 12 months of
spontaneous amenorrhea, or 6 months of spontaneous amen-
orrhea with serum FSH levels greater than 40 mIU/mL, or
6 weeks postsurgical bilateral oophorectomy, with or without
hysterectomy. All patients had moderate-to-severe vaginal
dryness according to the FDA guidelines for drug develop-
ment in postmenopausal women (Center for Drug Evaluation
and Research, CDER January 2003). A moderate symptom
was considered if the symptom was present, bothersome and
annoying, and a severe symptom was considered if the
symptom was present, bothersome and annoying, and inter-
fered with the normal activity. Other inclusion criteria were a
score 0 or 1 in the Eastern Cooperative Oncology Group
performance status (ECOG), and an adequate bone marrow
and organ function. Patients treated with another antitumoral
therapy (excluding pamidronate or alendronate) and those
who received vulvovaginal treatment in the 15 days before the
study start, and/or had used hormones, natural (phytoestro-
gens) or herbal products to treat menopausal symptoms in the
3 months before the study start were excluded from the study.
Other important exclusion criteria included the presence of
postmenopausal uterine bleeding, vaginal bleeding of
unknown etiology, and endometrial thickness greater than
or equal to 4 mm; and history of other malignancy within
5 years of study entry (aside from nonmelanoma skin cancer
or carcinoma-in-situ of the uterine cervix adequately treated),
thromboembolic disease or coagulopathies, severe cardiovas-
cular or respiratory disease in the previous 6 months, renal
impairment, Hepatitis B and/or C (with the exception of
patients with normal hepatic function), and HIV infection.
Patients who had received any investigational treatment for
any condition or had participated in any clinical trial within
4 weeks of inclusion date were excluded from the study. All
patients signed the written informed consent before starting
the treatment, and the study protocol was approved by the
Regulatory Authorities and applicable Ethics Committees of
the participating countries.
Intervention
The study was conducted in two phases: the safety phase
and the study phase. During the safety phase, a sentinel group
of 10 women was treated daily for three weeks with active
treatment (0.005% estriol vaginal gel, study drug) or placebo
(moisturizing gel) at a 4:1 ratio. The influence of treatment onMenopause, Vol. 27, No. 5, 2020 527
HIRSCHBERG ET ALeither the levels of systemic estrogens or gonadotropins was
assessed by an Independent Data Monitoring Committee.
Once the lack of influence on hormone levels was verified,
a minimum of 60 women (study group) were randomized to
receive either active treatment or placebo at a 4:1 ratio. The
study sponsor was responsible for the randomization list,
which was performed in blocks of 5. The study drug and
placebo had identical characteristics (appearance, smell, and
texture), and the investigators and patients were blinded to
randomization codes.
Both treatments were administered using an intravaginal
applicator at the dose of 1 g of gel per application (containing
50 mg of estriol for the active treatment) for 12 weeks: once
daily during the first three weeks, and twice weekly during
weeks 4 to 12. During the baseline visit, patients were
provided with the investigational products, administered
the first dose in the presence of the investigator, and were
instructed to administer the gel at bedtime. A screening visit
was scheduled within the two weeks prior to the baseline visit.
Follow-up visits were performed at weeks 1, 3, 8, and 12 of
treatment, and 30 5 days after the last dose (posttreatment
visit; only physical examination, general laboratory analysis,
and adverse events recording). Treatment compliance was
assessed by counting and recording the number of unused
applicators.
Efficacy and safety assessments
Efficacy assessments were performed at baseline, and
weeks 3 and 12, and included a gynecological examination
and the administration of the Female Sexual Function Index
(FSFI) questionnaire. Vaginal symptoms (ie vaginal dryness,
dyspareunia, and pruritus) and signs (ie mucosa with thinning
or flattening of folds, and fragility and dryness of the mucosa)
were rated by the patient (symptoms) and the investigator
(signs) on a 4-point scale, where 0 indicated the absence of
the sign/symptom and 3 indicated the symptom was considered
very irritating and severe; scores 1 and 2 indicated mild and
moderate signs/symptoms, respectively The vaginal pH was
measured on the vaginal secretion using a reactive strip (pH 2.0-
9.0). Vaginal maturation was assessed from two cytology
samples (drawn from the bottom of the right and left vaginal
sac, respectively), and were analyzed at a central laboratory
(Centro Anatomopatológico, S.L., Madrid, Spain). For the
cytological evaluation, the average percentages of parabasal,
intermediate, and superficial cells were calculated twice on 100
consecutive cells. The maturation index was determined using
the formula 0.2x (% parabasal)þ 0.6x (% intermediate)þ 1.0x
(% superficial) (range 20-100).19 The FSFI is a 19-item ques-
tionnaire, composed of three multi-item functional subscales
covering six domains (ie, desire, arousal, lubrication, orgasm,
satisfaction, and pain), developed specifically to assess sexual
functioning in the research setting.20 An algorithm was used to
determine domain scores and a composite full-scale score.
Safety was assessed based on the occurrence of adverse
events, endometrial changes from baseline to week 12 as
evidenced by ultrasound, and the changes in the serum levels528 Menopause, Vol. 27, No. 5, 2020of gonadotropins (FSH and luteinizing hormone [LH]) and
plasma levels of estrogens (estriol, estradiol, and estrone)
throughout treatment. Estrogen levels were determined at a
central laboratory (Pharm-Analyt, Austria) at baseline and
weeks 1, 3, 8, and 12. Due to the extremely low levels of
estrogens expected, estriol, estradiol, and estrone were ana-
lyzed using a validated ultrasensitive liquid chromatography
tandem mass spectrometry (LC-MS/MS) method. Values
below limit of quantification (1, 3 and 5 pg/ml) were consid-
ered 0.5, 1.5, and 2.5 pg/mL for estriol, estradiol, and estrone,
respectively. FSH and LH were analyzed by chemilumines-
cent immunoassay at Laboratorios Echevarne, Spain at the
same time points and, additionally, at the screening visit to
assess their physiological variability. Determinations for a
given participant were performed in the same batch. Other
safety assessments included laboratory parameters (hematol-
ogy, blood chemistry, and urine tests) and a physical and
gynecological examination (breast and pelvic examination),
performed at baseline and at weeks 3 and 12. All adverse
events were recorded and graded according to the Medical
Dictionary for Regulatory Activities. The causal relationship
between the investigational product and the adverse event was
assessed by the investigator using the Karch and Lasagna
algorithm.21
Statistics
Analyses regarding the change in gonadotropins were per-
formed in the intent-to-treat (ITT) population, which included
all 61 randomized participants; missing data were imputed
using the last observation carried forward method. Data miss-
ing in the efficacy analysis were not imputed. Categorical
variables were presented as frequency and percentage, whereas
quantitative variables were presented as the mean and standard
deviation (SD) or the median and interquartile range (IQR).
Results regarding the progression of signs and symptoms
severity throughout the follow-up period were presented as
both mean (SD) and median (IQR) to provide a comprehensive
view of que quantitative change, which in some cases occurred
in a narrow score range. Because of the high variability of
physiological levels of gonadotropins, the change in these
hormones was assessed by comparing the physiological vari-
ability (ie, difference between screening and baseline visits)
and the in-treatment variability (ie, difference from baseline to
12-week treatment). The between-group differences in score
change were compared using the nonparametric Mann-Whit-
ney-U test, whereas differences between time points within
each treatment group were compared using the Wilcoxon
signed-rank test (results are presented as mean and SD) All
analyses were performed using the statistical software SAS
Enterprise Guide 5.1.
RESULTS
Characteristics of Study Patients
Of 86 patients considered for eligibility, 61 were randomized
to receive either 0.005% estriol vaginal gel (n¼ 50) or placebo
moisturizing gel (n¼ 11) (Fig. 1). Nine patients, seven in the 2020 The Author(s)
active group and two in the placebo group, discontinued the baseline to 90.2 (72.8, 94.6) at week 3 and 65.2 (51.4,
FIG. 1. Flow diagram of the patients included in the study.
LOW DOSE ESTRIOL FOR VVA IN BREAST CANCERintervention but were nevertheless included in the analysis of
the ITT population. The ITT population included postmeno-
pausal women with mean (SD) age of 58.9 (7.6) and 61.4 (4.7)
years (active and placebo groups, respectively). Twenty-one
(34.4%) and 40 (65.6%) women complained of moderate- and
severe-vaginal dryness, respectively; 12 (19.7%) and 33 (54%)
from moderate and severe dyspareunia, respectively; and 36
(59%) from mild-to-severe pruritus. Table 1 summarizes the
baseline demographic and clinical characteristics of the study
participants. At baseline, patients in the two groups showed no
significant differences regarding vaginal pH and maturation,
the scores of the symptoms (ie, dyspareunia, pruritus, and
vaginal dryness) and signs (ie, dryness, fragility of the mucosa,
and vaginal mucosa with flattening of folds or thinning) of
vaginal atrophy (Table 2). Likewise, the scores of the FSFI
questionnaire (total and for each domain) were similar between
the two study groups.
Efficacy on maturation value and vaginal pH
The median (IQR) vaginal maturation scoring in the active
group increased significantly from 24.6 (21.3, 30.8) at75.0) at week 12 (P< 0.001 for each comparison with
baseline), and remained similar in the placebo group
(P¼ 0.717 and P¼ 0.244, for differences between baseline
and weeks 3 and 12, respectively) (Fig. 2). Correspondingly,
vaginal maturation values were significantly higher in the
active compared to the placebo treatment arm: mean (SD)
for active and placebo groups were 83.1 (17.7) and 32.4
(22.4) at week 3, and 61.0 (21.2) and 34.1 (18.1) at week 12,
respectively (P< 0.001, for each time point). A similar trend
was observed for vaginal pH: patients in the active group
experienced a significant decrease in median vaginal pH
from baseline (6.5, IQR 5.5, 7.5) to week 3 (4.5, IQR 4.5,
5.0) and week 12 (4.5, IQR 4.5, 5.5) (P< 0.001, for each
comparison with baseline). Conversely, no significant dif-
ferences were found between baseline and week 3 and
week 12 in the placebo group (P¼ 0.38 and P¼ 0.184,
respectively) (Fig. 2). Likewise, pH was significantly lower
in the active compared to the placebo treatment arm, with
mean (SD) values of 4.8 (0.8) and 6.5 (1.1) at week 3
(P< 0.001), and 5.1 (0.9) and 6.4 (1.4) at week 12
(P¼ 0.004), respectively.Menopause, Vol. 27, No. 5, 2020 529
TABLE 1. Baseline demographic, clinical and previous treatment characteristics of the study patients, n (%)
Active (n¼ 50) Placebo (n¼ 11) Total (n¼ 61)
Postmenopausal status
12 months of spontaneous amenorrhea 44 (88.0) 11 (100.0) 55 (90.2)
At least 6 weeks postsurgical bilateral oophorectomya 5 (10.0) 0 (0.0) 5 (8.2)
6 months of spontaneous amenorrhea with serum FSH increased levels > 40 mIU/mL 1 (2.0) 0 (0.0) 1 (1.6)
ECOG performance status
0 44 (88.0) 11 (100.0) 55 (90.2)
1 5 (10.0) 0 (0.0) 5 (8.2)
Not available 1 (2.0) 0 (0.0) 1 (1.6)
Breast cancer stage
I 18 (36.0) 4 (36.4) 22 (36.1)
IIA 23 (46.0) 3 (27.3) 26 (42.6)
IIB 7 (14.0) 2 (18.2) 9 (14.8)
IIIA 2 (4.0) 2 (18.2) 4 (6.6)
Estrogen receptor
Positive 50 (100.0) 11 (100.0) 61 (100.0)
Progesterone receptor
Negative 11 (22.0) 2 (18.2) 13 (21.3)
Positive 38 (76.0) 9 (81.8) 47 (77.0)
Not available 1 (2.0) 0 (0.0) 1 (1.6)
HER2
Negative 37 (74.0) 8 (72.7) 45 (73.8)
Positive 13 (26.0) 3 (27.3) 16 (26.2)
Previous adjuvant hormonal treatments
Aromatase inhibitors 41 (82.0) 10 (90.9) 51 (83.6)
Aromatase inhibitorsþtamoxifen 8 (16.0) 1 (9.1) 9 (14.8)
Aromatase inhibitorsþtamoxifenþLHRH agonist 1 (2.0) 0 (0.0) 1 (1.6)
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; LHRH, luteinizing hormone-releasing hormone.
aIncluding patients with and without hysterectomy.
HIRSCHBERG ET ALEfficacy of symptoms and signs of vulvovaginal atrophy
Patients in the active group, but not those in the placebo
group, experienced a significant decrease in the scores of
dyspareunia, pruritus, fragility of the mucosa, and mucosa
with flattening of folds or thinning between baseline, week 3,
and week 12. Conversely, the scores for vaginal dryness
(symptom) and dryness (sign) significantly decreased in the
active and, to a minor extent, in the placebo group after 3 and
12 weeks of treatment (Fig. 3). A similar trend was observedTABLE 2. Baseline scores of symptoms and signs of vaginal a
median (percen
A
Maturation value 24.6 (
Vaginal pH 6.5 (
Symptoms of vaginal atrophy
Dyspareunia 3.0 (
Pruritus 1.0 (
Vaginal dryness 3.0 (
Total score 6.0 (
Signs of vaginal atrophy
Dryness 2.0 (
Fragility of the mucosa 2.0 (
Vaginal mucosa with flattening of folds or thinning 2.0 (








Total Score 14.3 (
FSFI, Female Sexual Function Index.
aMann-Whitney-U test.
530 Menopause, Vol. 27, No. 5, 2020for the total scores of symptoms and signs of vaginal atrophy,
which significantly decreased in the active and, to a minor
extent, in the placebo group at the follow-up visits (Fig. 4).
The extent of the change in the scores of vulvovaginal
symptoms and signs in the active and placebo groups through-
out the follow-up period is summarized in Table 3. Changes in
total symptom score between baseline and the two follow-up
visits were significantly greater in the active group compared
to the placebo group. Regarding individual symptoms, thetrophy and FSFI scores, according to treatment allocation,
tile 25.75)
ctive Placebo P valuea
21.3,30.8) 23.4 (21.0,24.6) 0.180
5.5,7.5) 7.0 (5.5,8.0) 0.550
2.0,3.0) 3.0 (2.0,3.0) 0.100
0.0,2.0) 0.0 (0.0,2.0) 0.540
2.0,3.0) 3.0 (2.0,3.0) 0.590
6.0,7.0) 6.0 (6.0,8.0) 0.680
2.0,3.0) 3.0 (2.0,3.0) 0.140
1.0,3.0) 2.0 (2.0,3.0) 0.520
2.0,3.0) 2.0 (2.0,2.0) 0.130
5.0,8.0) 7.0 (6.0,8.0) 0.710
1.2,2.4) 1.2 (1.2,2.4) 1.000
0.0,2.7) 1.8 (0.0,2.7) 0.820
0.0,2.4) 1.4 (0.0,2.4) 0.980
0.0,2.4) 2.6 (0.0,4.8) 0.320
2.0,3.2) 2.4 (2.4,4.0) 0.460
0.0,5.2) 2.4 (0.0,5.2) 0.880
5.4,18.4) 18.3 (5.1,22.4) 0.470
 2020 The Author(s)
FIG. 2. Boxplot of the vaginal maturation (A) and vaginal pH (B) values determined at each of the indicated visits in the active treatment and placebo
groups (ITT population). ITT, intent-to-treat.
LOW DOSE ESTRIOL FOR VVA IN BREAST CANCERassessment of vaginal dryness at week 12 yielded significant
differences between groups. On the other hand, all the signs
analyzed and the total signs score showed statistically signifi-FIG. 3. Individual scores of each symptom (A) and signs (B) of vulvovagina
and IQR, respectively. Symptoms/signs severity are presented on a 0-3 scale:
baseline; IQR, interquartile range; w, week. P< 0.001,  P< 0.05 for diffcant differences between active and placebo groups at week 3
and week 12, except for fragility of the mucosa, whose
changes were statistically significant only at week 12.l atrophy throughout treatment. Columns and error bars represent median
0¼ lack of symptoms/signs, 1¼mild, 2¼moderate, and 3¼ severe. BL,
erences between baseline and the given visit.
Menopause, Vol. 27, No. 5, 2020 531
FIG. 4. Total scores of symptoms (A) and signs (B) of vulvovaginal
atrophy throughout treatment. Columns and error bars represent median
and IQR, respectively. BL, baseline; IQR, interquartile range; w, week.
P< 0.001,  P< 0.05 for differences between baseline and the given
visit.
HIRSCHBERG ET ALImpact on sexual function
Although patients in the placebo group did not show
significant differences after treatment, those in the active
group experienced a progressive and significant increase in
the FSFI total score from baseline, a trend that was maintained
in the individual analysis of the desire, arousal, lubrication,
orgasm, and satisfaction domains, but not in the pain domain
(Table 4). Despite the significant improvement in mostTABLE 3. Changes in vaginal maturation value, vaginal pH,
Baseline-wee
Active (n¼ 44) Placeb
Maturation value 53.4 (21.9) 9.2 (2
62.0 (70.4,37.8) 0.6 (
Vaginal pH 1.8 (1.3) 0.3 (1
2.0 (0.5,2.5) 0.5 (
Symptoms
Vaginal dryness 1.3 (0.9) 0.8 (0
1.0 (1.0,2.0) 1.0 (0
Dyspareunia 1.3 (0.9) 0.8 (0
1.0 (1.0,2.0) 1.0 (0
Pruritus 0.5 (1.0) 0.2 (1
0.0 (0.0,1.0) 0.0 (
Total score symptoms 3.5 (2.0) 1.8 (1
3.0 (2.0,4.5) 1.0 (0
Signs
Dryness of the mucosa 1.7 (0.8) 0.7 (0
2.0 (1.0,2.0) 1.0 (0
Fragility of the mucosa 1.0 (0.9) 0.5 (0
1.0 (0.0,2.0) 0.0 (0
Mucosa with thinning or flattening of folds 1.1 (0.8) 0.2 (0
1.0 (1.0,2.0) 0.0 (0
Total score signs 3.8 (1.9) 1.5 (1
4.0 (2.0,5.0) 1.0 (0
All values in bold are considered significant according to the threshold establish
Results are described as mean (standard deviation) (upper row) and median (per
using the Mann-Whitney-U test.
532 Menopause, Vol. 27, No. 5, 2020domains observed only in the active group, the pairwise
comparison at each visit did not reveal significant differences
between active and placebo groups regarding the total FSFI
score and the scores of each domain.
Safety
Patients treated with estriol gel did not experience significant
changes in FSH levels (median difference between physiologi-
cal and in-treatment variability after 12 weeks of treatment was
2.8 [IQR 13.1; 7.4]; P¼ 0.104) and LH levels (0.8 [IQR
5.3; 2.9]; P¼ 0.116; N¼ 61). In the active group, median
estriol levels slightly increased at week 1 and progressively
normalized over the treatment period. The levels of the key
hormones at each study visit are summarized in Supplementary
Table 1 (Supplementary file 1, http://links.lww.com/MENO/
A532). The median and IQR of both estrone and estradiol were
persistently below the limit of quantification at all study visits
for both groups. During the 16 weeks of follow-up (including
the posttreatment visit), no deaths or serious adverse events
(SAEs) related to the treatment were reported. An SAE unre-
lated to the study treatment consisting of non-Hodgkin’s lym-
phoma appeared before the administration of the study
treatment and resulted in study discontinuation. Eight nonseri-
ous adverse events were reported once each in six patients in the
active group: breast tenderness, vulvovaginal inflammation,
vulvovaginal pruritus, burning sensation, diarrhea, vomiting,
mucosal dryness, and pyrexia.
DISCUSSION
In this phase II, randomized, double-blind, placebo-con-
trolled clinical trial, we provide scientific evidence regardingand the scores of symptoms and signs of vaginal atrophy
k 3 Baseline-week 12
o (n¼ 11) P value Active (n¼ 45) Placebo (n¼ 10) P value
2.4) 31.8 (23.8) 10.9 (18.5)
11.6,2.0) <0.0001 37.2 (50.0,5.4) 1.0 (36.4,1.4) <0.01
.3) 1.6 (1.4) 0.5 (1.4)
0.5,1.0) <0.001 1.3 (0.5,2.5) 0.5 (0.0,1.5) 0.058
.9) 1.8 (0.9) 0.9 (1.0)
.0,1.0) 0.14 2.0 (1.0,2.0) 1.0 (1.0,1.0) <0.01
.7) 1.6 (1.0) 1.1 (1.1)
.0,1.0) 0.14 2.0 (1.0,2.5) 1.0 (0.0,2.0) 0.25
.3) 0.7 (1.3) 0.3 (1.2)
1.0,2.0) 0.29 0.0 (0.0,2.0) 0.0 (0.0,1.0) 0.34
.8) 4.6 (2.1) 2.6 (2.4)
.5,3.0) 0.03 4.5 (3.0,7.0) 2.0 (1.5,4.0) 0.04
.6) 1.7 (0.9) 0.8 (0.8)
.0,1.0) <0.001 2.0 (1.0,2.0) 1.0 (0.0,1.0) <0.01
.9) 1.4 (0.8) 0.5 (0.5)
.0,1.0) 0.13 1.5 (1.0,2.0) 0.5 (0.0,1.0) <0.01
.4) 1.5 (0.9) 0.3 (0.5)
.0,0.0) <0.001 1.0 (1.0,2.0) 0.0 (0.0,1.0) <0.001
.4) 4.6 (2.1) 1.6 (1.5)
.0,2.0) <0.001 5.0 (4.0,6.0) 1.0 (1.0,3.0) <0.001
ed for this analysis.
centile 25.75) (lower row). Between-group differences were analyzed
 2020 The Author(s)
TABLE 4. FSFI domain and total scores throughout treatment, median (percentile 25.75)
Baseline (N¼ 57) Week 3 (N¼ 51) Week 12 (N¼ 55) P valuea BL-w3 P valuea BL-w12
Domains
Desire
Active 1.2 (1.2,2.4) 2.4 (1.2,3.0) 2.4 (1.2,3.6) <0.001 <0.001
Placebo 1.2 (1.2,2.4) 2.1 (1.2,2.4) 2.4 (1.2,3.0) 0.563 0.484
Arousal
Active 1.5 (0.0,2.7) 2.1 (0.6,3.6) 2.7 (0.9,4.8) <0.001 <0.001
Placebo 1.8 (0.0,2.7) 1.7 (0.0,3.0) 2.7 (0.3,3.6) 0.688 1.000
Lubrication
Active 1.2 (0.0,2.4) 3.0 (0.0,4.8) 3.3 (0.0,5.1) <0.001 <0.001
Placebo 1.4 (0.0,2.4) 2.1 (0.0,2.4) 2.3 (0.3,5.1) 0.594 0.234
Orgasm
Active 1.2 (0.0,2.4) 2.4 (0.0,4.4) 3.2 (0.0,4.4) 0.008 <0.001
Placebo 2.6 (0.0,4.8) 2.0 (0.0,2.8) 3.8 (0.0,5.2) 0.594 0.680
Satisfaction
Active 2.4 (2.0,3.2) 3.8 (2.2,5.0) 4.8 (3.4,5.4) <0.001 <0.001
Placebo 2.4 (2.4,4.0) 3.8 (2.4,4.8) 4.2 (2.0,5.2) 0.469 0.391
Pain
Active 0.8 (0.0,5.2) 1.4 (0.0,3.4) 1.2 (0.0,3.6) 0.117 0.157
Placebo 2.4 (0.0,5.2) 2.4 (0.0,4.8) 1.6 (0.0,4.4) 1 0.563
Total score
Active 14.3 (5.4,18.4) 18.0 (6.0, 24.2) 21.7 (17.7, 26.0) 0.007 <0.001
Placebo 18.3 (5.1,22.4) 18.0 (10.4,20.2) 20.1 (5.0,23.7) 0.875 0.438
All values in bold are considered significant according to the threshold established for this analysis.
BL, baseline; FSFI, Female Sexual Function Index.
aSigned rank test (Wilcoxon).
LOW DOSE ESTRIOL FOR VVA IN BREAST CANCERthe efficacy and safety of 0.005% estriol vaginal gel for the
treatment of genital symptoms in postmenopausal women
receiving NSAI adjuvant therapy for hormone receptor-posi-
tive early breast cancer. After 12 weeks of treatment, the local
application of the ultra-low dose of estriol gel reversed most
of the vulvovaginal symptoms and signs associated with deep
estrogen deprivation in BSCs receiving adjuvant treatment,
including the most common and bothersome symptoms
(ie vaginal dryness and dyspareunia), resulting in a positive
impact on sexual function.
Vulvovaginal symptoms of menopause are a highly preva-
lent side effect of adjuvant hormonal treatments in BCSs,
particularly in women receiving NSAIs, who experience
vaginal dryness more frequently compared to women receiv-
ing tamoxifen.6 In spite of the widespread use of local estro-
gens for reversing this and other symptoms and signs of
vulvovaginal atrophy in healthy postmenopausal women,
clinical evidence supporting the safety and efficacy of local
application of estrogens in BCSs is scarce.8,10,22 Our results
regarding the efficacy of the product in reducing the signs/
symptoms burden were similar to those of previous trials
investigating other estrogen formulations containing either
estradiol or estriol at higher doses such as estradiol ring and
tablets (7.5 and 12.5 mg, respectively), estriol ovules (0.5 mg)
and cream (0.25 mg), and estriol tablets (0.03 mg) containing
Lactobacillus acidophilus.3,23,24 In spite of the lesser estro-
genic action of estriol (compared to estradiol) and the 10-fold
lower dose (compared to other estriol products widely indi-
cated for this use), the ultra-low dose of estriol used in this
study (50 mg per application dose) showed efficacy in revers-
ing the changes in the vaginal epithelium associated with the
deep estrogen deprivation in postmenopausal BCSs receivingNSAIs, providing clinical evidence that this population could
benefit from local estrogen treatment.
Interestingly, although the intensity of most symptoms and
signs of vaginal atrophy remained unchanged in the placebo
treatment arm, the scores of vaginal dryness (sign and symp-
tom) experienced a significant—albeit modest— reduction
after 3 and 12 weeks of placebo treatment. Given that the
0.005% estriol gel is formulated as a highly hydrating gel with
a true effect beyond the pure placebo effect, treatment with
the gel alone (without hormones) was expected to have an
effect on some of the symptoms and signs (ie temporal relief
of vaginal dryness), similar to the lubricants and moisturizers
indicated as first-line treatment for vaginal atrophy.2,4,8 Nev-
ertheless, patients in the active arm experienced a greater
improvement in vaginal dryness throughout the follow-up,
likely due to the stimulation of maturation of the vaginal
epithelium by the active hormone and its healing effect.
Regarding sexual function, only the 0.005% estriol gel
improved most domains and the total score of the FSFI
questionnaire, whereas the placebo hydrating gel failed to
improve sexual function. Given the predominant impact of
NSAIs treatment on sexual function and consequently, well-
being and quality of life, these findings suggest that the ultra-
low 0.005% estriol vaginal gel may improve patients’ quality
of life in addition to alleviating GSM symptoms.25
Although studies with local estrogens in BCSs receiving
NSAIs are scarce, the efficacy of local estrogen treatment,
such as low-dose estriol, in alleviating symptoms and signs of
vulvovaginal atrophy in healthy postmenopausal women is
well documented.26 In this regard, a previous pivotal phase III
placebo-controlled study including 167 women reported effi-
cacy of the 0.005% estriol ultra-low dose vaginal gel.12Menopause, Vol. 27, No. 5, 2020 533
5. Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer:
HIRSCHBERG ET ALHence, irrespective of the cause of estrogen deprivation (ie,
natural vs NSAIs-associated), the 0.005% estriol gel effec-
tively reversed the changes in the vaginal epithelium associ-
ated with estrogen deprivation.
In spite of the randomized placebo-controlled nature of this
trial, our analysis was constrained to a 12-week follow-up,
thus precluding long-term assessment of the effects of estriol.
Some authors have reported an increased absorption in atro-
phic compared to estrogenized vaginal tissues and a differen-
tial expression of estrogen receptors in the vaginal walls of
pre- and post-menopausal women.27,28 Although these obser-
vations likely rule out increased absorption of estriol by the
well estrogenized epithelium and, consequently, safety con-
cerns after prolonged treatment, long-term studies may be
needed to assess the sustained safety and effectivity through-
out the prescribed adjuvant treatment. It is also worth men-
tioning that the scarcity of previous data regarding the change
of FSH in patients treated with estriol vaginal gels precluded a
formal estimation of sample size; however, the results of a
previous analysis of FSH change in these patients suggested
that the size of our sample should be large enough to identify
significant changes in FSH levels.24 Given that our results
indicate that the 0.005% estriol gel preparation is effective
and safe, further studies using a larger sample size (with a
balanced randomization) to assess long-term effects are
warranted.
CONCLUSIONS
Our results provide clinical evidence on the efficacy of
0.005% estriol vaginal gel in postmenopausal breast cancer
survivors treated with NSAI. Despite the ultra-low dose of
estriol, the application of the gel is safe and improves vaginal
symptoms and signs, including vaginal pH and maturation,
associated with the depletion of estrogens that occurs in these
patients, resulting in improved sexual function. The negligible
impact of the product on the levels of estrogens, FSH, and LH
supports the safe use of this ultra-low dose estriol vaginal gel
as a treatment option for vulvovaginal atrophy in BSCs
receiving NSAIs.
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